Home > Insider Trading > Filing (0000899243-20-008496)

Filing Details

Accession Number:: 0000899243-20-008496
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2020-03-16 17:18:16
Reporting Period:: 2020-03-16

Accepted Time:: 2020-03-16 17:18:16
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1672619	Imara Inc.	IMRA	()	4

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1591318	Barbara Dalton	235 E 42Nd St New York NY 10017		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2020-03-16	1,245,222	$0.00	1,245,222	No	4	C	Indirect	By entities affiliated with Pfizer Inc.
Common Stock	Acquisiton	2020-03-16	312,500	$16.00	1,557,722	No	4	P	Indirect	By entities affiliated with Pfizer Inc.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By entities affiliated with Pfizer Inc.
No	4	P	Indirect	By entities affiliated with Pfizer Inc.

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series Seed Preferred Stock	Disposition	2020-03-16	478,749	$0.00	76,003	$0.00
Common Stock	Series A Preferred Stock	Disposition	2020-03-16	5,470,492	$0.00	868,467	$0.00
Common Stock	Series B Preferred Stock	Disposition	2020-03-16	1,894,444	$0.00	300,752	$0.00
Common Stock	Stock Option (right to buy)	Acquisiton	2020-03-16	15,457	$0.00	15,457	$16.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
15,457	2030-03-15	No	4	A	Direct

Footnotes

On March 16, 2020, the Issuer's Series Seed Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
On March 16, 2020, the Issuer's Series A Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
On March 16, 2020, the Issuer's Series B Preferred Stock converted into Common Stock on a 6.299-for-1 basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series B Preferred Stock was convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The shares had no expiration date.
The reporting person is Vice President of Venture Capital at Pfizer, Inc., an affiliate of Pfizer Ventures (US) LLC. The reporting person disclaims beneficial ownership of the shares owned by the entities affiliated with Pfizer Ventures (US) LLC except to the extent of her pecuniary interest therein.
The option vests in three equal installments on March 16, 2021, 2022 and 2023.